Quote:

---

ohm or anyone else knowledgeable: I've been seeing that other mabs that are coming through with good trial results sometimes have 'cytokine release syndrome' as a frequent side effect (with one trial of a combination of talquetamab and talquistamab it was 79%). Would LL be a good addition to that treatment regimen to preclude that effect? Or would it conflict with the action of the other mabs?

---

Cytokine release syndrome is the equivalent of a cytokine storm with the same bad effects. The talquetamab and talquistamab combo activates T-cells that can kill tumor cells. The downside is no control of the inflammatory effects by doing so. Leronlimab also boosts killer T-cells but lowers the inflammatory effects. So leronlimab can supplant talquetamab and talquistamab and reduce Tregs, angiogenesis and it has other benefits.